SEC Form 4 · accession 0001209191-17-064811
Denali Therapeutics Inc. · DNLI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David P Schenkein
Director
Period of report
Dec 7, 2017
Accepted (ET)
Dec 8, 2017 · 5:59 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001714899
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $18.00 | Dec 7, 2017 | A | 47,165 | A | — | Dec 6, 2027 | Common Stock | 47,165 | 47,165 | D |
Explanation of responses
- F125% of the shares subject to the option shall vest on December 7, 2018 and an additional 1/48 of the shares vest monthly thereafter.